Contact Us
Drug Search Results
More Filters [+]

BMS-387032

Alternative Names: bms-387032, sns-032
Latest Update: 2023-09-28
Latest Update Note: PubMed Publication

Product Description

SNS-032, (formerly BMS-387032) is a potent and selective inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/17938863/)

Mechanisms of Action: CDK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Viracta Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BMS-387032

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Chronic Lymphoid Leukemia|Multiple Myeloma|Lymphoma, B-Cell|Adenocarcinoma|Mantle-Cell Lymphoma|Lymphocytic Chronic B-Cell Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
SPO-0009

P1

Completed

Multiple Myeloma|Lymphoma, B-Cell|Mantle-Cell Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia

2008-12-01

SPO-0007

P1

Completed

Adenocarcinoma

None

Recent News Events

Date

Type

Title

09/28/2023

PubMed

 Degradation of Cyclin-Dependent Kinase 9/Cyclin T1 by Optimized Microtubule-Associated Protein 1 Light Chain 3 Beta-Recruiting Coumarin Analogs.

07/01/2023

PubMed

 In silico enhancer mining reveals SNS-032 and EHMT2 inhibitors as therapeutic candidates in high-grade serous ovarian cancer.

02/16/2023

PubMed

 Piperlongumine conjugates induce targeted protein degradation.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions